Y-Intercept (HK)’s Castle Biosciences CSTL Stock Holding History

Y-Intercept (HK)’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$761K	Buy	31,916 +8,415	+36%	+$187K	0.02%	1158
2026 Q1	$577K	Buy	23,501 +10,255	+77%	+$336K	0.01%	1227
2025 Q4	$515K	Buy	+13,246	New	+$427K	0.01%	1229
2025 Q3	–	Sell	-78,938	Closed	-$1.61M	–	1649
2025 Q2	$1.61M	Buy	+78,938	New	+$1.46M	0.04%	701
2025 Q1	–	Sell	-21,839	Closed	-$582K	–	1270
2024 Q4	$582K	Sell	21,839 -2,367	-10%	-$72.1K	0.04%	661
2024 Q3	$690K	Buy	24,206 +845	+4%	+$21.5K	0.04%	618
2024 Q2	$509K	Sell	23,361 -1,242	-5%	-$27.7K	0.03%	798
2024 Q1	$545K	Buy	24,603 +14,010	+132%	+$305K	0.04%	669
2023 Q4	$229K	Buy	+10,593	New	+$186K	0.02%	941

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Y-Intercept (HK)'s CSTL Position: Q2 2026 in Review

Y-Intercept (HK) increased its Castle Biosciences (CSTL) stake by 36% in Q2 2026, buying an estimated $187K and bringing the position to 31,916 shares worth $761K. The position accounts for 0.02% of the portfolio, ranked #1158.

Y-Intercept (HK) first reported a position in CSTL in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.61M in Q2 2025. 9 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Y-Intercept (HK) held 31,916 shares of Castle Biosciences worth $761K as of Q2 2026.
Y-Intercept (HK) bought 8,415 Castle Biosciences shares in Q2 2026, an estimated $187K.
Castle Biosciences made up 0.02% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1158 holding.
Y-Intercept (HK) first reported a position in Castle Biosciences in Q4 2023 and has held it in 9 quarters since.
Y-Intercept (HK)'s Castle Biosciences position peaked at $1.61M in Q2 2025.
9 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.